Human VTCN1 Stable Cell Line - CT26

The VTCN1 gene, also known as B7-H4, B7S1, or B7x, encodes a member of the B7 family of costimulatory proteins that functions as a negative regulator of T cell activation. This immune checkpoint molecule is expressed on the surface of antigen-presenting cells and is frequently overexpressed in various human cancers, including ovarian, breast, renal, and endometrial carcinomas, where it contributes to immune evasion by suppressing T cell proliferation and cytokine production. The Human VTCN1 Stable Cell Line - CT26 is generated by stably transfecting the mouse CT26 colon carcinoma cell line with the full-length human VTCN1 gene, resulting in surface expression of the human B7-H4 protein on the CT26 background. This cell line is designed for use in both in vitro and in vivo studies, providing a reliable and consistent tool for evaluating the interaction between human B7-H4 and its receptors on immune cells.

This stable cell line serves as a valuable platform for a range of research applications in immuno-oncology and drug development. It is particularly well suited for screening and characterizing B7-H4-targeting biologics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. Researchers can use this cell line to assess the binding affinity and specificity of candidate therapeutics, as well as to evaluate their functional activity in co-culture assays with T cells or other immune effector cells. The CT26 background also allows for subcutaneous implantation in immunocompetent BALB/c mice, making it a practical model for studying the in vivo efficacy of immune checkpoint inhibitors and chimeric antigen receptor (CAR)-T cell therapies targeting B7-H4. Additionally, the cell line can be employed in downstream signaling studies to investigate the molecular mechanisms underlying B7-H4-mediated immune suppression. By providing a consistent and reproducible source of human VTCN1-expressing cells, this product supports both early-stage target validation and preclinical evaluation of novel immunotherapeutic candidates.